Advertisement

Journal of Endocrinological Investigation

, Volume 34, Issue 5, pp 349–352 | Cite as

High prevalence of breast cancer in patients with benign thyroid diseases

  • I. Muller
  • A. Pinchera
  • E. Fiore
  • V. Belardi
  • V. Rosellini
  • E. Giustarini
  • C. Giani
Original Articles

Abstract

Background: In patients with breast cancer (BC) a high prevalence of benign thyroid diseases (BTD) has been described, Hashimoto’s thyroiditis accounting to a large extent for this association. The aim of this study was to evaluate the prevalence of BC in a large group of patients with BTD. Patients: Clinical records of 622 consecutive patients with BTD were examined. BC prevalence in BTD patients was compared with BC frequency in general population living in the same country. Results: BC prevalence in patients with BTD (38/622; 6.11%) was significantly higher (p=0.0002) compared to BC frequency in general population (2.07%). When patients were divided according to the age of menopause, in females older than 49 yr BC frequency in BTD was significantly higher than in age-matched population (7.6 vs 3.3%; p=0.006), while in females aged 30–49 yr BC frequency in BTD was higher, but not statistically significantly, than in age-matched population (3.7 vs 0.5%; p=0.06). No significant difference in BC prevalence was found when patients were grouped according to the diagnosis of thyroid disorders: Graves’ disease, Hashimoto’s thyroiditis, nodular goiter associated or not associated with serum thyroid autoantibodies (TAb). No significant difference in BC frequency was observed between TAb+ (26/377; 6.9%) and TAb- (12/245; 4.9%) patients. The distribution of known risk factors for breast malignancies was similar in patients with or without BC. Conclusion: In patients with BTD the prevalence of BC is significantly higher than the expected, showing the usefulness of screening for breast malignancy of patients with BTD.

Key-words

Breast cancer benign thyroid disease thyroid autoimmunity nodular goiter 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chalstrey LJ, Benjamin B. High incidence of breast cancer in thyroid cancer patients. Br J Cancer 1966, 20: 670–5.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Myhill J, Reeve TS, Hales IB. Thyroid function in breast cancer. Acta Endocrinol (Copenh) 1966, 51: 290–300.Google Scholar
  3. 3.
    Sicher K, Waterhouse JA. Thyroid activity in relation to prognosis in mammary cancer. Br J Cancer 1967, 21: 512–8.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Goldman MB. Thyroid diseases and breast cancer. Epidemiol Rev 1990, 12: 16–28.PubMedGoogle Scholar
  5. 5.
    Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. Cancer Res 1990, 50: 2283–9.PubMedGoogle Scholar
  6. 6.
    Smyth PP. Thyroid disease and breast cancer. J Endocrinol Invest 1993, 16: 396–401.PubMedCrossRefGoogle Scholar
  7. 7.
    Turken O, Narln Y, Demlrbas S, et al. Breast cancer in association with thyroid disorders. Breast Cancer Res 2003, 5: R110–3.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Mittra I, Perrin J, Kumaoka S. Thyroid and other autoantibodies in British and Japanese women: an epidemiological study of breast cancer. Br Med J 1976, 1: 257–9.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Ito K, Maruchi N. Breast cancer in patients with Hashimoto’s thyroiditis. Lancet 1975, 2: 1119–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Rasmusson B, Feldt-Rasmussen U, Hegedüs L, Perrild H, Bech K, Høier-Madsen M. Thyroid function in patients with breast cancer. Eur J Cancer Clin Oncol 1987, 23: 553–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Maruchi N, Annegers JF, Kurland LT. Hashimoto’s thyroiditis and breast cancer. Mayo Clin Proc 1976, 51: 263–5.PubMedGoogle Scholar
  12. 12.
    Giani C, Fierabracci P, Bonacci R, et al. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 1996, 81: 990–4.PubMedGoogle Scholar
  13. 13.
    Giustarini E, Pinchera A, Fierabracci P, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol 2006, 154: 645–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Fiore E, Giustarini E, Mammoli C, et al. Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest 2007, 30: 734–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Garner CN, Ganetzky R, Brainard J, et al. Increased prevalence of breast cancer among patients with thyroid and parathyroid disease. Surgery 2007, 142: 806–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Sioka C, Fotopoulos A. Association of thyroid cancer with breast cancer. Surgery 2009, 145: 123–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Agarwal DP, Soni TP, Sharma OP, Sharma S. Synchronous malignancies of breast and thyroid gland: a case report and review of literature. J Cancer Res Ther 2007, 3: 172–3.PubMedCrossRefGoogle Scholar
  18. 18.
    Weiss HA, Brinton LA, Potischman NA, et al. Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol 1999, 28: 816–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Simon MS, Tang MT, Bernstein L, et al. Do thyroid disorders increase the risk of breast cancer? Cancer Epidemiol Biomarkers Prev 2002, 11: 1574–8.PubMedGoogle Scholar
  20. 20.
    Moseson M, Koenig KL, Shore RE, Pasternack BS. The influence of medical conditions associated with hormones on the risk of breast cancer. Int J Epidemiol 1993, 22: 1000–9.PubMedCrossRefGoogle Scholar
  21. 21.
    De Angelis R, Grande E, Inghelmann R, et al. Cancer prevalence estimates in Italy from 1970 to 2010. Tumori 2007, 93: 392–7.PubMedGoogle Scholar
  22. 22.
    Rago T, Chiovato L, Grasso L, Pinchera A, Vitti P. Thyroid ultrasonography as a tool for detecting thyroid autoimmune diseases and predicting thyroid dsfunction in apparently healthy subjects. J Endocrinol Invest 2001, 24: 763–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Marcocci C, Vitti P, Cetani F, Catalano F, Concetti R, Pinchera A. Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J Clin Endocrinol Metab 1991, 72: 209–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab 1999, 84: 561–6.PubMedGoogle Scholar
  25. 25.
    Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000, 6: 871–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Stoddard FR 2nd, Brooks AD, Eskin BA, Johannes GJ. Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. Int J Med Sci 2008, 5: 189–96.PubMedCrossRefGoogle Scholar
  27. 27.
    Bonacci R, Pinchera A, Fierabracci P, Gigliotti A, Grasso L, Giani C. Relevance of estrogen and progesterone receptors enzyme immunoassay in malignant, benign and surrounding normal thyroid tissue. J Endocrinol Invest 1996, 19: 159–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Giani C, Campani D, De Negri F, et al. Interference of thyroperoxidase on immuno-cytochemical determination of steroid receptors in thyroid tissue. J Endocrinol Invest 1993, 16: 37–43PubMedCrossRefGoogle Scholar
  29. 29.
    Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab 2001, 86: 1072–7.PubMedGoogle Scholar
  30. 30.
    Rajoria S, Suriano R, Shanmugam A, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 2010, 20: 33–41.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007, 109: 1972–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Holm LE, Hall P, Wiklund K, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991, 83: 1072–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Hoffman DA, McConahey WM, Fraumeni JF Jr, Kurland LT. Cancer incidence following treatment of hyperthyroidism. Int J Epidemiol 1982, 11: 218–24.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2011

Authors and Affiliations

  • I. Muller
    • 1
  • A. Pinchera
    • 1
  • E. Fiore
    • 1
  • V. Belardi
    • 1
  • V. Rosellini
    • 1
  • E. Giustarini
    • 1
  • C. Giani
    • 1
  1. 1.Department of EndocrinologyUniversity of PisaPisaItaly

Personalised recommendations